We are live on ! Find out more
CDLX icon

Cardlytics

111 hedge funds and large institutions have $99.2M invested in Cardlytics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $5M | Put options by funds: $2.64M

15% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 33

0.73% less ownership

Funds ownership: 6.93%6.19% (-0.73%)

13% less funds holding

Funds holding: 127111 (-16)

38% less funds holding in top 10

Funds holding in top 10: 85 (-3)

50% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 30

66% less capital invested

Capital invested by funds: $288M → $99.2M (-$189M)

Holders
111
Holders Change
-16
Holders Change %
-12.6%
% of All Funds
1.59%
Holding in Top 10
5
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-37.5%
% of All Funds
0.07%
New
15
Increased
38
Reduced
33
Closed
30
Calls
$5M
Puts
$2.64M
Net Calls
+$2.37M
Net Calls Change
+$424K

CDLX Hedge Fund Activity: Q3 2024 in Review

111 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cardlytics (CDLX) for Q3 2024, worth a combined $99.2M — down 66% from $288M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of CDLX and 15 opened new positions — a net loss of 15 holders — while 33 trimmed existing stakes and 38 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $2.69M. The largest seller was Morgan Stanley, cutting an estimated $10M.

  • 111 institutional investors held Cardlytics (CDLX) as of Q3 2024, down from 127 in Q2 2024.
  • Funds reported $99.2M of Cardlytics stock for Q3 2024, down 66% quarter-over-quarter.
  • 15 funds opened new Cardlytics positions in Q3 2024 and 30 closed out, a net change of -15 holders.
  • The largest Cardlytics buyer in Q3 2024 was D.E. Shaw & Co, an estimated $2.69M added.
  • The largest Cardlytics seller in Q3 2024 was Morgan Stanley, an estimated $10M sold.

Based on aggregated 13F filings for Q3 2024.